Package Leaflet: Information for the User
Aranesp 10 micrograms solution for injection in pre-filled syringe
Aranesp 15 micrograms solution for injection in pre-filled syringe
Aranesp 20 micrograms solution for injection in pre-filled syringe
Aranesp 30 micrograms solution for injection in pre-filled syringe
Aranesp 40 micrograms solution for injection in pre-filled syringe
Aranesp 50 micrograms solution for injection in pre-filled syringe
Aranesp 60 micrograms solution for injection in pre-filled syringe
Aranesp 80 micrograms solution for injection in pre-filled syringe
Aranesp 100 micrograms solution for injection in pre-filled syringe
Aranesp 130 micrograms solution for injection in pre-filled syringe
Aranesp 150 micrograms solution for injection in pre-filled syringe
Aranesp 300 micrograms solution for injection in pre-filled syringe
Aranesp 500 micrograms solution for injection in pre-filled syringe
darbepoetin alfa (darbepoetin alfa)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Your doctor has prescribed Aranesp (an anti-anaemic) for the treatment of your anaemia. Anaemia occurs when the blood does not contain enough red blood cells and the symptoms can be tiredness, weakness, and shortness of breath.
Aranesp works in exactly the same way as the natural hormone erythropoietin. Erythropoietin is produced in the kidneys and helps the bone marrow to produce more red blood cells. The active substance of Aranesp is darbepoetin alfa, produced by genetic engineering in Chinese Hamster Ovary (CHO-K1) cells.
If you have chronic kidney disease
Aranesp is used to treat symptomatic anaemia associated with chronic kidney disease (kidney failure) in adults and children. In kidney failure, the kidney does not produce enough of the natural hormone erythropoietin, which can often cause anaemia.
As your body will need some time to produce more red blood cells, it will take about four weeks before you notice any effect. Your normal dialysis routine will not affect Aranesp's ability to treat your anaemia.
If you are receiving chemotherapy
Aranesp is used to treat symptomatic anaemia in adult patients with non-myeloid tumours receiving chemotherapy.
One of the main side effects of chemotherapy is that it stops the bone marrow from producing enough red blood cells. Towards the end of chemotherapy treatment, especially if you have received a lot of chemotherapy, your red blood cell count may decrease, causing anaemia.
Do not use Aranesp:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using Aranesp.
Tell your doctor if you haveor have had:
Special precautions:
If you experience a severe rash or any of these skin symptoms, stop taking Aranesp and inform your doctor or seek immediate medical attention.
Using Aranesp with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Ciclosporin and tacrolimus (medicines that suppress the immune system) may be affected by the number of red blood cells in the blood. It is important that you tell your doctor if you are using any of these medicines.
Using Aranesp with food and drink
Food and drink do not affect Aranesp.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Aranesp has not been used in pregnant women. It is important that you tell your doctor if you:
It is not known whether darbepoetin alfa is excreted in breast milk. If you are treated with Aranesp, you should stop breast-feeding.
Driving and using machines
Aranesp should not affect your ability to drive or use machines.
Aranesp contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".
Follow exactly the instructions for administration of this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist again.
After some blood tests, your doctor has decided that you need Aranesp because your haemoglobin level is 10 g/dl or less. Your doctor will tell you how much Aranesp you need and how often you should use it to keep your haemoglobin level between 10 and 12 g/dl. This may vary depending on whether you are an adult or a child.
How to inject Aranesp yourself
Your doctor may decide that it is better for you or the people taking care of you to inject Aranesp. Your doctor, nurse, or pharmacist will teach you how to inject the pre-filled syringe. Do not try to inject yourself if you have not been taught how to do it. Never inject Aranesp yourself into a vein.
If you have chronic kidney disease
For all adult and paediatric patients ≥ 1 year of age with chronic kidney disease, Aranesp is given as a single injection, under the skin (subcutaneously) or into a vein (intravenously).
To correct anaemia, the initial dose of Aranesp per kilogram of body weight will be:
For adult patients not on dialysis, 1.5 micrograms/kg once a month may also be used as the initial dose.
For all adult and paediatric patients ≥ 1 year of age with chronic kidney disease, once your anaemia is corrected, you will continue to receive Aranesp as a single injection, either once a week or once every two weeks. For all adult and paediatric patients ≥ 11 years of age who are not on dialysis, Aranesp may also be given as a monthly injection.
Your doctor will regularly take blood samples to see how your anaemia is responding to treatment and, if necessary, may need to adjust the dose every four weeks to maintain long-term control of your anaemia.
Your doctor will use the lowest effective dose to control the symptoms of your anaemia.
If you do not respond adequately to Aranesp, your doctor will review your dose and inform you if you need to change the doses of Aranesp.
Your doctor will regularly check your blood pressure, especially at the start of treatment.
In some cases, your doctor may recommend that you take iron supplements.
Your doctor may decide to change the way you are given the injection (under the skin or into a vein). If this happens, you will start with the same dose you were receiving before and will have blood tests to check that your anaemia is still being treated correctly.
If your doctor has decided to change your treatment from r-HuEPO (genetically engineered erythropoietin) to Aranesp, they will choose to give you Aranesp either once a week or once every two weeks. The route of administration will be the same as with r-HuEPO, but your doctor will decide how much and when you should be given it, and may adjust the dose you receive if necessary.
If you are receiving chemotherapy
Aranesp is given under the skin as a single injection, once a week or once every three weeks.
To correct anaemia, the initial dose of Aranesp will be:
Your doctor will regularly take blood samples to measure how your anaemia is responding, and may adjust the dose as necessary. Treatment will continue until about 4 weeks after the end of chemotherapy. Your doctor will tell you exactly when to stop taking Aranesp.
In some cases, your doctor may recommend that you take iron supplements.
If you use more Aranesp than you should
You may have serious problems if you inject more Aranesp than you should, such as very high blood pressure. Contact your doctor or pharmacist if this happens. If you do not feel well, contact your doctor or pharmacist immediately.
If you forget to use Aranesp
Do not take a double dose to make up for forgotten doses.
If you forget to inject a dose of Aranesp, contact your doctor to see when you should inject the next dose.
If you stop using Aranesp
If you want to stop using Aranesp, you should first discuss this with your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some patients have experienced the following side effects using Aranesp:
Patients with chronic kidney disease
Very common:may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
Frequency not known:frequency cannot be estimated from the available data
Patients with cancer
Very common:may affect more than 1 in 10 people
Common:may affect up to 1 in 10 people
Uncommon:may affect up to 1 in 100 people
All patients
Frequency not known:frequency cannot be estimated from the available data
Stop taking Aranesp if you experience these symptoms and inform your doctor or seek immediate medical attention. See also section 2.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the label after “EXP”. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C - 8°C). Do not freeze. Do not use Aranesp if you think it has been frozen.
Keep the pre-filled syringe in the outer packaging to protect it from light.
Once you have removed your syringe from the refrigerator and left it at room temperature for about 30 minutes before injecting, you must use it within 7 days or discard it.
Do not use this medicine if you notice that the contents of the pre-filled syringe are cloudy or contain particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Aranesp Composition
Appearance of the Product and Container Contents
Aranesp is a clear, colorless or slightly opalescent injectable solution in a pre-filled syringe.
Aranesp is available in packs of 1 or 4 pre-filled syringes. The syringes are supplied in blisters (packs of 1 and 4 syringes) or without blisters (packs of 1 syringe). Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Amgen Europe B.V.
Minervum 7061
NL-4817 ZK Breda
Netherlands
Marketing Authorization Holder
Amgen Europe B.V.
Minervum 7061
NL-4817 ZK Breda
Netherlands
Manufacturer
Amgen Technology (Ireland) Unlimited Company
Pottery Road
Dun Laoghaire
Co Dublin
Ireland
Manufacturer
Amgen NV
Telecomlaan 5-7
1831 Diegem
Belgium
For further information about this medicinal product, please contact the local representative of the marketing authorization holder.
België/Belgique/Belgien s.a. Amgen n.v. Tel/Tél: +32 (0)2 7752711 | Lietuva Amgen Switzerland AG Vilniaus filialas Tel: +370 5 219 7474 |
България Amgen Bulgaria EOOD Тел.: +359 (0)2 424 7440 | Luxembourg/Luxemburg s.a. Amgen Belgique/Belgien Tel/Tél: +32 (0)2 7752711 |
Česká republika Amgen s.r.o. Tel: +420 221 773 500 | Magyarország Amgen Kft. Tel.: +36 1 35 44 700 |
Danmark Amgen, filial af Amgen AB, Sverige Tlf: +45 39617500 | Malta Amgen B.V. The Netherlands Tel: +31 (0)76 5732500 |
Deutschland AMGEN GmbH Tel.: +49 89 1490960 | Nederland Amgen B.V. Tel: +31 (0)76 5732500 |
Eesti Amgen Switzerland AG Vilniaus filialas Tel: +372 586 09553 | Norge Amgen AB Tel: +47 23308000 |
Ελλάδα Amgen Ελλάς Φαρμακευτική Ε.Π.Ε. Τηλ.: +30 210 3447000 | Österreich Amgen GmbH Tel: +43 (0)1 50 217 |
España Amgen S.A. Tel: +34 93 600 18 60 | Polska Amgen Biotechnologia Sp. z o.o. Tel.: +48 22 581 3000 |
France Amgen S.A.S. Tél: +33 (0)9 69 363 363 | Portugal Amgen Biofarmacêutica, Lda. Tel: +351 21 4220550 |
Hrvatska Amgen d.o.o. Tel: +385 (0)1 562 57 20 | România Amgen România SRL Tel: +4021 527 3000 |
Ireland Amgen Limited United Kingdom Tel: +44 (0)1223 420305 | Slovenija AMGEN zdravila d.o.o. Tel: +386 (0)1 585 1767 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Amgen Slovakia s.r.o. Tel: +421 2 321 114 49 |
Italia Amgen S.r.l. Tel: +39 02 6241121 | Suomi/Finland Amgen AB, sivuliike Suomessa/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900500 |
Κύπρος C.A. Papaellinas Ltd Τηλ.: +357 22741 741 | Sverige Amgen AB Tel: +46 (0)8 6951100 |
Latvija Amgen Switzerland AG Rigas filiale Tel: +371 257 25888 | United Kingdom Amgen Limited Tel: +44 (0)1223 420305 |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu.
This leaflet is available in all EU/EEA languages on the European Medicines Agency website.
This section contains information on how to inject Aranesp yourself. It is important that you do not attempt to inject yourself if your doctor, nurse, or pharmacist has not shown you how to do it. If you have any questions about how to inject, ask your doctor, nurse, or pharmacist.
How should you or the person injecting you use the Aranesp pre-filled syringe?
Your doctor has prescribed Aranesp in a pre-filled syringe and you should inject the contents into the tissue under the skin. Your doctor, nurse, or pharmacist will tell you how much Aranesp you need and how often you should inject it.
Materials:
For injection, you will need:
What should you do before injecting Aranesp subcutaneously?
How to prepare the Aranesp injection?
Before injecting Aranesp, do the following:
|
Where should you inject Aranesp?
The best places to inject Aranesp yourself are the top of the thighs and the abdomen. If someone else is injecting you, they can also inject it into the back of your arms. If you notice redness or swelling at the injection site, you can change the injection site. |
How to inject Aranesp?
Remember:If you have any problems, do not hesitate to ask your doctor or nurse for help and advice.
How to dispose of used syringes?